What's Happening?
The University of Oxford has commenced the world's first phase I clinical trial for a vaccine targeting the Bundibugyo Ebola virus (BDBV), which is currently causing an outbreak in central Africa. The trial, known as the BD-Ebov study, is being conducted
by the Oxford Vaccine Group and involves 50 healthy adults aged 18-55. Recruitment is underway, with dosing pending approval from the UK medicines regulator. This trial follows the recent declaration of a public health emergency by the WHO due to the Ebola outbreak in the Democratic Republic of the Congo and Uganda. The vaccine, ChAdOx1 BDBV, is based on the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine. The Serum Institute of India is collaborating with Oxford University, having manufactured and stockpiled 620,000 doses of the vaccine candidate. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the trial, with $8.6 million allocated to the ChAdOx1 BDBV vaccine.
Why It's Important?
This trial represents a significant step in addressing the Bundibugyo Ebola virus, a rare species of Ebola with no existing vaccine. The outbreak has resulted in 1,792 confirmed cases and 625 deaths, posing a severe public health challenge, especially in remote and conflict-affected regions. The development of a vaccine could potentially curb the spread of the virus and prevent future outbreaks. The collaboration between Oxford University and the Serum Institute of India highlights the importance of international partnerships in tackling global health crises. The trial's success could also bolster confidence in the use of viral vector platforms for vaccine development, as demonstrated by the COVID-19 vaccine.
What's Next?
Pending regulatory approval, the trial will proceed with dosing and monitoring of participants to evaluate the vaccine's safety, tolerability, and immune response. If successful, the trial could pave the way for larger-scale studies and eventual deployment in affected regions. The WHO's identification of ChAdOx1 BDBV as a promising candidate underscores the urgency of advancing through clinical phases. The outcome of this trial could influence future funding and research priorities for Ebola and other infectious diseases.
